Navigation Links
Experimental drug reduces brain damage, eliminates brain hemorrhaging in rodents afflicted by stroke
Date:10/25/2013

An experimental drug called 3K3A-APC appears to reduce brain damage, eliminate brain hemorrhaging and improve motor skills in older stroke-afflicted mice and stroke-afflicted rats with comorbid conditions such as hypertension, according to a new study from Keck Medicine of the University of Southern California (USC).

The study, which appears online today in the journal Stroke, provides additional evidence that 3K3A-APC may be used as a therapy for stroke in humans, either alone or in combination with the FDA-approved clot-busting drug therapy tPA (tissue plasminogen activator). Clinical trials to test the drug's efficacy in people experiencing acute ischemic stroke are expected to begin recruiting patients in the U.S. in 2014.

"Currently, tPA is the best treatment for stroke caused by a blocked artery, but it must be administered within three hours after stroke onset to be effective," said Berislav V. Zlokovic, M.D., Ph.D., director of the Zilkha Neurogenetic Institute (ZNI) at the Keck School of Medicine of USC and the study's lead investigator. "Because of this limited window, only a small fraction of those who suffer a stroke reach the hospital in time to be considered for tPA. Our studies show that 3K3A-APC extends tPA's therapeutic window and counteracts tPA's tendency to induce bleeding in the brains of animals having a stroke."

Zlokovic is the scientific founder of ZZ Biotech, a Houston-based biotechnology company he co-founded with USC benefactor Selim Zilkha to develop biological treatments for stroke and other neurological ailments. ZZ Biotech's 3K3A-APC is a genetically engineered variant of the naturally occurring activated protein C (APC), which plays a role in the regulation of blood clotting and inflammation. 3K3A-APC has been shown to have a protective effect on the lining of blood vessels in rodent brains, which appears to help prevent bleeding caused by tPA.

In collaboration with Cedars-Sinai Medical Center and The Scripps Research Institute, Zlokovic and his team gave tPA alone and in combination with 3K3A-APC to mature female mice and male hypertensive rats four hours after stroke. They also gave 3K3A-APC in regular intervals up to seven days after stroke. They measured the amount of brain damage, bleeding and motor ability of the rodents up to four weeks after stroke.

The researchers found that, under those conditions, tPA therapy alone caused bleeding in the brain and did not reduce brain damage or improve motor ability when compared to the control. The combination of tPA and 3K3A-APC, however, reduced brain damage by more than half, eliminated tPA-induced bleeding and significantly improved motor ability.

"Scientists all around the globe are studying potential stroke therapies, but very few have the robust preclinical data package that 3K3A-APC has," said Kent Pryor, Ph.D., M.B.A., ZZ Biotech's chief operating officer. "The results from Dr. Zlokovic's studies have been very promising."

Zlokovic's team previously reported similar results in young, healthy male rodents. A Phase 1 trial testing the safety of 3K3A-APC in healthy human volunteers, led by study co-author Patrick D. Lyden, M.D., of Cedars-Sinai, concluded in February.

"We now have opened an investigational new drug application at the FDA to conduct a Phase 2 clinical trial of 3K3A-APC in patients experiencing acute ischemic stroke," said Joe Romano, CEO and president of ZZ Biotech. "We are excited to see 3K3A-APC move from healthy volunteers to real patients suffering from this terrible disease."


'/>"/>

Contact: Alison Trinidad
alison.trinidad@usc.edu
323-442-3941
University of Southern California - Health Sciences
Source:Eurekalert

Related biology news :

1. Nicole George wins 2012 Journal of Experimental Biology Outstanding Paper Prize
2. Experimental drug combination selectively destroys lymphoma cells
3. Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
4. Bridges experimental and bioinformatics perspectives to delineate protein-DNA interactions
5. New findings on tree nuts and health presented at the Experimental Biology Meeting in Boston, Mass.
6. AMP joins the Federation of American Societies for Experimental Biology
7. Soy-based S-equol supplement reduces metabolic syndrome risk factors
8. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
9. Laparoscopy reduces the risk of small-bowel obstruction
10. Hot sauce ingredient reduces beer belly fat as a weight-loss surgery alternative
11. The absence of elephants and rhinoceroses reduces biodiversity in tropical forests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... Holly Springs, North Carolina (PRWEB) , ... May ... ... comprehensive process automation and building management solutions and services based in Aurora, Ohio, ... a decade of established business in the Research Triangle Park area, this new ...
(Date:5/20/2016)... ... 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural ... to treat the disease. Surviving Mesothelioma has just posted an article on the new ... institutions based their mesothelioma study on the fact the Manumycin A, a derivative of ...
(Date:5/19/2016)... ... 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, a ... Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 years ... preclinical and clinical safety programs. “We’ve seen significant demand for, and we are ...
(Date:5/18/2016)... The Biotech industry continues to face ... there are no opportunities ahead. Today, ActiveWallSt.com has on its ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ), ... (NASDAQ: OPHT ). Sign up now to receive ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained 0.68%, ...
Breaking Biology Technology: